Core Viewpoint - The article discusses the recent inclusion of three Chinese biotechnology companies in the U.S. Entity List, highlighting the ongoing tensions in the biotechnology sector between the U.S. and China, particularly in relation to national security concerns and technological competition [2][3]. Group 1: U.S. Policy Developments - On September 12, the U.S. Department of Commerce's Bureau of Industry and Security (BIS) announced the addition of 23 Chinese entities to the Entity List due to actions deemed contrary to U.S. national security or foreign policy interests, including three from the biotechnology and life sciences sector [2]. - The entities listed will require export licenses for all items governed by the Export Administration Regulations (EAR), with a presumption of denial for such licenses, indicating a significant barrier for these companies in international trade [2]. Group 2: Companies Listed - The three biotechnology companies added to the Entity List are: 1. Beijing Tianyi Huiyuan Biotech, established in 2008, focuses on gene sequence detection, gene synthesis, gene editing, and protein expression vector assembly, serving various hospitals and research institutions [3]. 2. Beijing Tsingke Biotech Co., Ltd., founded in 2017, operates as a comprehensive gene synthesis platform, providing a range of services including gene synthesis, antibody proteins, and molecular reagents, and has attracted significant investment, including a B-round financing of 400 million RMB [4]. 3. Sangon Biotech (Shanghai) Co., Ltd., founded in 2003, offers over 20,000 products across seven categories, including DNA synthesis and sequencing, and has a global presence in 147 countries, recognized as a major player in the DNA synthesis market [5].